News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
696,258 Results
Type
Article (39564)
Company Profile (247)
Press Release (656447)
Section
Business (204103)
Career Advice (2007)
Deals (35412)
Drug Delivery (94)
Drug Development (81015)
Employer Resources (172)
FDA (16155)
Job Trends (14843)
News (345053)
Policy (32502)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2547)
Accelerated approval (2)
Adcomms (20)
Allergies (80)
Alliances (49368)
ALS (83)
Alzheimer's disease (1354)
Antibody-drug conjugate (ADC) (108)
Approvals (16157)
Artificial intelligence (230)
Autoimmune disease (16)
Automation (14)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (101)
Biotechnology (175)
Bladder cancer (58)
Brain cancer (24)
Breast cancer (248)
Cancer (2002)
Cardiovascular disease (162)
Career advice (1673)
Career pathing (29)
CAR-T (139)
Cell therapy (395)
Cervical cancer (19)
Clinical research (65724)
Collaboration (766)
Compensation (455)
Complete response letters (19)
COVID-19 (2580)
CRISPR (35)
C-suite (211)
Cystic fibrosis (98)
Data (1965)
Decentralized trials (2)
Denatured (16)
Depression (38)
Diabetes (249)
Diagnostics (6333)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (112)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (85)
Earnings (86209)
Editorial (31)
Employer branding (21)
Employer resources (146)
Events (111680)
Executive appointments (646)
FDA (17264)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (687)
Gene editing (96)
Generative AI (18)
Gene therapy (277)
GLP-1 (685)
Government (4379)
Grass and pollen (4)
Guidances (48)
Healthcare (18812)
Huntington's disease (22)
IgA nephropathy (22)
Immunology and inflammation (103)
Indications (26)
Infectious disease (2711)
Inflammatory bowel disease (131)
Inflation Reduction Act (8)
Influenza (47)
Intellectual property (87)
Interviews (311)
IPO (16484)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (34)
Layoffs (453)
Leadership (15)
Legal (7900)
Liver cancer (70)
Lung cancer (292)
Lymphoma (134)
Machine learning (4)
Management (58)
Manufacturing (267)
MASH (61)
Medical device (13321)
Medtech (13326)
Mergers & acquisitions (19402)
Metabolic disorders (632)
Multiple sclerosis (70)
NASH (16)
Neurodegenerative disease (79)
Neuropsychiatric disorders (24)
Neuroscience (1831)
NextGen: Class of 2025 (6513)
Non-profit (4476)
Northern California (2430)
Now hiring (37)
Obesity (340)
Opinion (201)
Ovarian cancer (72)
Pain (77)
Pancreatic cancer (76)
Parkinson's disease (134)
Partnered (20)
Patents (203)
Patient recruitment (93)
Peanut (46)
People (57094)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20469)
Phase II (28946)
Phase III (21570)
Pipeline (1041)
Podcasts (45)
Policy (113)
Postmarket research (2563)
Preclinical (8656)
Press Release (64)
Prostate cancer (94)
Psychedelics (30)
Radiopharmaceuticals (244)
Rare diseases (357)
Real estate (5900)
Recruiting (65)
Regulatory (22144)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (3)
RNA editing (4)
RSV (39)
Schizophrenia (64)
Series A (120)
Series B (78)
Service/supplier (11)
Sickle cell disease (51)
Southern California (2104)
Special edition (14)
Spinal muscular atrophy (148)
Sponsored (28)
Startups (3571)
State (2)
Stomach cancer (13)
Supply chain (59)
The Weekly (27)
United States (21202)
Vaccines (657)
Venture capitalists (37)
Webinars (12)
Weight loss (224)
Women's health (33)
Worklife (15)
Date
Today (154)
Last 7 days (748)
Last 30 days (2807)
Last 365 days (33599)
2025 (8111)
2024 (35218)
2023 (40076)
2022 (51174)
2021 (55714)
2020 (54091)
2019 (46544)
2018 (35021)
2017 (32109)
2016 (31485)
2015 (37554)
2014 (31321)
2013 (26345)
2012 (28571)
2011 (29263)
2010 (27330)
Location
Africa (718)
Alabama (49)
Alaska (7)
Arizona (224)
Arkansas (13)
Asia (37709)
Australia (6166)
California (5537)
Canada (1871)
China (475)
Colorado (247)
Connecticut (256)
Delaware (128)
Europe (80864)
Florida (822)
Georgia (194)
Idaho (57)
Illinois (498)
India (23)
Indiana (290)
Iowa (9)
Japan (142)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (829)
Massachusetts (4172)
Michigan (209)
Minnesota (370)
Mississippi (2)
Missouri (77)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1583)
New Mexico (28)
New York (1596)
North Carolina (919)
North Dakota (7)
Northern California (2430)
Ohio (191)
Oklahoma (14)
Oregon (33)
Pennsylvania (1258)
Puerto Rico (9)
Rhode Island (26)
South America (1094)
South Carolina (18)
South Dakota (1)
Southern California (2104)
Tennessee (93)
Texas (826)
Utah (164)
Virginia (130)
Washington D.C. (57)
Washington State (512)
West Virginia (3)
Wisconsin (49)
696,258 Results for "neuron23 inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Neuron23 Announces Publication in PNAS Highlighting the Important Role of TYK2 in Neuroimmunology
March 26, 2025
·
3 min read
Press Releases
Neuron23 to Present Phase 1 Healthy Volunteer Data of NEU-411, a Brain-penetrant LRRK2 Inhibitor, at AD/PD™ 2025
March 24, 2025
·
3 min read
Press Releases
Neuron23 Unveils Groundbreaking Phase 2 Trial in Early Parkinson’s Disease
November 19, 2024
·
7 min read
Press Releases
Neuron23 Announces Usage of Roche’s Digital Biomarker and Device in Parkinson’s Disease Clinical Trial
November 19, 2024
·
4 min read
Business
Neuron23 Appoints Andrew Yost, MBA, as Chief Business Officer
Neuron23™ Inc. today announced the appointment of Andrew Yost, MBA, as the company’s chief business officer (CBO).
August 22, 2023
·
3 min read
Press Releases
Neuron23 Announces First-in-human Dose in Phase 1 Clinical Trial of NEU-111, a TYK2 Inhibitor with Best-in-class Potential for Immune-mediated Inflammatory Disorders
December 4, 2024
·
2 min read
Business
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
Neuron23™ Inc. and QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration to develop a companion diagnostic for Neuron23’s LRRK2 inhibitor for Parkinson’s disease.
September 14, 2022
·
7 min read
Drug Development
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson’s Disease
Neuron23™ Inc. today announced that the Company recently initiated dosing in a Phase 1 clinical trial of NEU-723 for the treatment of Parkinson’s disease.
February 7, 2023
·
4 min read
Business
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and Neuron23 Inc. today announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase (LRRK2) inhibitor for Parkinson’s disease.
September 14, 2022
·
7 min read
Business
Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer
Neuron23™ Inc. today announced the appointment of Sam Jackson, M.D., MBA, as the company’s first chief medical officer (CMO).
April 12, 2022
·
2 min read
1 of 69,626
Next
